Avalo Therapeutics (AVTX) Share-based Compensation (2014 - 2026)

Avalo Therapeutics has reported Share-based Compensation for 13 years, with the latest figure at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 10.31% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $14.0 million (up 64.87% YoY), and the FY2025 full-year result was $13.6 million, up 132.76% from the prior year.
• Share-based Compensation for Q1 2026 stood at $3.6 million, down from $4.5 million in the prior quarter.
• The five-year high for Share-based Compensation was $5.3 million in Q1 2022, with the low at $471000.0 in Q2 2024.
• Historically, Share-based Compensation has averaged $2.0 million across 5 years, with a median of $953000.0 in 2023.
• Annual changes were most pronounced in 2023 — Share-based Compensation slumped 83.9% — and 2025, when it soared 477.07%.
• Avalo Therapeutics' Share-based Compensation stood at $843000.0 in 2022, then decreased by 7.95% to $776000.0 in 2023, then soared by 274.23% to $2.9 million in 2024, then surged by 55.23% to $4.5 million in 2025, then slipped by 20.7% to $3.6 million in 2026.
• The last three Share-based Compensation figures came in at $3.6 million (Q1 2026), $4.5 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.